Phase II Study of Weekly Paclitaxel for Relapsed and Refractory Small Cell Lung Cancer

The purpose of this study was to evaluate the efficacy and toxicity of single-agent paclitaxel given weekly to patients with relapsed and refractory small cell lung cancer (SCLC). Patients were treated with 80 mg/m 2 paclitaxel administered weekly for 1 h for 6 weeks in an 8-week cycle. Twenty-two p...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-01, Vol.26 (1B), p.777-781
Main Authors: YAMAMOTO, Nobuyuki, TSURUTANI, Junji, YOSHIMURA, Naruo, ASAI, Gyo, MORIYAMA, Azusa, NAKAGAWA, Kazuhiko, KUDOH, Shinzo, TAKADA, Minoru, MINATO, Yoshiaki, FUKUOKA, Masahiro
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - adverse effects
Biological and medical sciences
Carcinoma, Small Cell - drug therapy
Drug Administration Schedule
Female
Humans
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Pneumology
Tumors
Tumors of the respiratory system and mediastinum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate the efficacy and toxicity of single-agent paclitaxel given weekly to patients with relapsed and refractory small cell lung cancer (SCLC). Patients were treated with 80 mg/m 2 paclitaxel administered weekly for 1 h for 6 weeks in an 8-week cycle. Twenty-two patients were enrolled, 21 of whom were eligible. The patient characteristics included: 20 males, 1 female; median age 66 years (range 48 - 75); performance status 0/1 in 19 and 2 in 5 patients. Grade 3/4 leukopenia and neutropenia occurred in 47.5% and 64%, respectively. Other grade 3/4 toxicities included infection, skin rash, neuropathy and pulmonary toxicity. There were 5 partial responses in 3 out of the 11 sensitive cases and 2 out of the 10 refractory cases, respectively. Paclitaxel, administered as a weekly infusion at a dose of 80 mg/m 2 , was effective in treating relapsed and refractory SCLC.
ISSN:0250-7005
1791-7530